⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5265505 | 0.68 | — | — | |
| SCHEMBL5912796 | 0.68 | — | — | |
| SCHEMBL14724457 | 0.65 | — | — | |
| SCHEMBL5352401 | 0.64 | — | — | |
| SCHEMBL6238180 | 0.61 | — | — | |
| SCHEMBL12468775 | 0.60 | — | — | |
| SCHEMBL6238176 | 0.59 | — | — | |
| SCHEMBL7153806 | 0.58 | — | — | |
| SCHEMBL14729711 | 0.58 | — | — | |
| SCHEMBL4859224 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139613-B2 | Macrocyclic compounds and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-22 | — | — | US | disclosed |
| US-9119853-B2 | Sanglifehrin based compounds | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-01 | — | — | US | disclosed |
| EP-2533784-B1 | SANGLIFEHRIN BASED COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-04-22 | — | — | EP | disclosed |
| EP-2691413-B1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-12-24 | — | — | EP | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| EP-2691413-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | Neurovive Pharmaceutical AB (SE) | 2014-02-05 | — | — | EP | disclosed |
| EP-2533784-A1 | SANGLIFEHRIN BASED COMPOUNDS | Biotica Technology Limited (GB) | 2012-12-19 | — | — | EP | disclosed |
| US-20120295841-A1 | Sanglifehrin Based Compounds | Abliva Ab (SE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012131377-A1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2011144924-A1 | AMINE OR AMID ANALOGUES OF SANGLIFEHRIN | BIOTICA TECHNOLOGY LIMITED (GB) | 2011-11-24 | — | — | WO | disclosed |
| US-7504513-B2 | Thiazolyl-benzimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| WO-2009011697-A1 | RNA OLIGONUCLEOTIDES TARGETING EBV AND HOST GENES AND THEIR USE FOR TREATMENT OF NASOPHARYNGEAL CARCINOMAS | OLIGOS ETC. INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080255119-A1 | DIPHENYL-DIHYDRO-IMIDAZOPYRIDINONES | DOMINIQUE ROMYR | 2008-10-16 | — | — | US | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| US-20050064407-A1 | Bcl-2 dnazymes | SUN LUN-QUAN (AU) | 2005-03-24 | — | — | US | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| EP-1402007-A1 | BCL-2 DNAZYMES | Johnson & Johnson Research Pty Limited (AU) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002099090-A1 | BCL-2 DNAZYMES | JOHNSON & JOHNSON RESEARCH PTY LTD (AU) | 2002-12-12 | — | — | WO | disclosed |
| EP-0397044-B1 | Arylsulfonamides, medicines containing these compounds and process for their preparation | THOMAE GMBH DR K (DE) | 1995-12-27 | — | — | EP | disclosed |